Home
The basics
Use cases
Events
Ask a question

Press Escape to close this navigation.

The basics
Use cases
Events
Ask a question

Popular Searches:

Disease Area

NSCLC
Breast
Pan-tumor
Colorectal
Melanoma

Topics

Real-world endpoints
FDA
Artificial intelligence
Bias

Formats

ResearchX session
Publication summary
Conference recaps
Case study

Authors

Amy Abernethy
Richard Pazdur
Blythe Adamson
Scott Ramsey
Neal Meropol

The basics

Key definitions
Real-world endpoints
Latest FDA thinking on RWE
How to best use RWE

Featured use cases

Biomarker prioritization
Trial design
Label expansion
Post marketing requirements
HTA and market access

Case studies

Label update
Label expansion
New drug application
Assessing unmet need

Featured articles

Temporal considerations for HTAs that use RWD
Overcoming missing survival data in RWD
How biotechs can use RWD to accelerate pipelines
What can RWE tell us about racial and ethnic disparities?

About Flatiron

For life sciences
For academics
Ask a question
Career opportunities

Featured videos

Pre-market use case for tumor agnostic RWD
Post-market use case for tumor-agnostic RWD
From NICE: Can early US adoption of therapies inform HTA decision-making?
An intro to RWE for HTA and market access

Interested in working with Flatiron evidence?

Click here to get started

Sign up for our monthly RWE Newsletter:

Newsletter Sign up

Visit flatiron.com
© 2021 Flatiron Health, Inc.
Legal & Privacy